AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39672583 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver steatosis
Number of subjects: 1816
Study 39672583 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver fibrosis
Number of subjects: 1816
Study 39672583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 1816
Study 39672583 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for steatosis
Number of subjects: 1816
Study 39672583 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for fibrosis
Number of subjects: 1816
Study 39672815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab, reslizumab, or dupilumab
Number of subjects: 8
Study 39672984 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically tailored meals (MTM) with medical nutrition therapy (MNT) - home delivery of 12 medically tailored frozen meals and a fresh produce bag weekly for 3 months, plus monthly calls with a registered dietitian for 6 months.
Number of subjects: 74
Study 39672984 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study 39672984 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically tailored meals (MTM) with medical nutrition therapy (MNT)
Number of subjects: 74
Study 39672986 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 218
Study 39672986 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic datasets from stored biospecimens
Number of subjects: 218
Study 39673015 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PD-L1 targeted peptide PET/CT
Number of subjects: 20
Study 39673053 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/Severe OSA
Number of subjects: 80
Study 39673053 — intervention group
Group type: COMPARATOR
Intervention: Mild OSA
Number of subjects: 80
Study 39673053 — intervention group
Group type: COMPARATOR
Intervention: Patients without OSA and/or ND
Number of subjects: 80
Study 39673171 — intervention group
Group type: COMPARATOR
Intervention: High-dose denosumab (120 mg/month with loading doses on weeks 2 and 3) for 6 months
Number of subjects: 8
Study 39673171 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose denosumab (120 mg/3 months)
Number of subjects: 8
Study 39673281 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing of subjects without conventional risk factors
Number of subjects: 1950
Study 39673281 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of mutations from CABP1, HLA-E, TOE1, and HPSE2
Number of subjects: 1950
Study 39673281 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular matrix-associated CHST14 and fibrinogen-associated KLHL8
Number of subjects: 1950
Study 39673298 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily coffee consumption (>5 cups/day)
Number of subjects: 0
Study 39673298 — intervention group
Group type: COMPARATOR
Intervention: Daily coffee consumption (<1 cup/day)
Number of subjects: 0
Study 39673311 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-cfDNA-guided biopsy
Number of subjects: 40
Study 39673311 — intervention group
Group type: COMPARATOR
Intervention: Clinician-guided biopsy
Number of subjects: 40
Study 39673311 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-cfDNA monitoring
Number of subjects: 40
Study 39673334 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 2.5 mg subcutaneous injections daily from Day 1 of ovarian stimulation until oocyte retrieval
Number of subjects: 288
Study 39673334 — intervention group
Group type: COMPARATOR
Intervention: Standard ovarian stimulation without adjuvant therapy (Control)
Number of subjects: 288
Study 39673334 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 288
Study 39673367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab + OIT (n=84)
Number of subjects: 148
Study 39673367 — intervention group
Group type: COMPARATOR
Intervention: Placebo + OIT (n=39)
Number of subjects: 148
Study 39673396 — intervention group
Group type: EXPERIMENTAL
Intervention: Leniolisib
Number of subjects: 148
Study 39673396 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 148
Study 39673415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 400 mg intravenous infusion at Weeks 0, 4, and 8, followed by 200 mg subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Number of subjects: 33
Study 39673415 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenous infusion at Weeks 0, 4, and 8, followed by placebo subcutaneous injections at Week 12 and every 4 weeks through Week 48, in addition to background therapy.
Number of subjects: 33
Study 39673415 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab + background therapy
Number of subjects: 33
Study 39673415 — intervention group
Group type: COMPARATOR
Intervention: Placebo + background therapy
Number of subjects: 33
Study 39673443 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mNC-FET
Number of subjects: 528
Study 39673443 — intervention group
Group type: COMPARATOR
Intervention: Postponed mNC-FET
Number of subjects: 528
Study 39673447 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) via endoscopic injection
Number of subjects: 9
Study 39673452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg (≥ 60 kg) or 200 mg (≥ 20 to < 60 kg) subcutaneously every 2 weeks for 24 weeks
Number of subjects: 24
Study 39673452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 24
Study 39673591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triapine (100 mg, five days a week for five weeks) with weekly IV cisplatin chemoradiation
Number of subjects: 21
Study 39673658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (DMF)
Number of subjects: 5124
Study 39673713 — intervention group
Group type: EXPERIMENTAL
Intervention: Freethiadine
Number of subjects: 40
Study 39673713 — intervention group
Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 40
Study 39673746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (OV) 125mg QID for 4 weeks
Number of subjects: 15
Study 39673779 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 142
Study 39673779 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 142
Study 39673810 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib at individualized starting dose (ISD) 200 mg/day
Number of subjects: 139
Study 39673820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin group
Number of subjects: 792
Study 39673820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 792
Study 39673820 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients above sBP 154, 159 and 160 mmHg or dBP 101 mmHg at baseline
Number of subjects: 792
Study 39673909 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-led reinstruction and remotivation of nursing staff by dental assistants (DAs) over 13 months
Number of subjects: 358
Study 39673909 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (similar interventions prescribed without reinstruction and remotivation)
Number of subjects: 358
Study 39674007 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme Gradient Boosting (XGBoost) algorithm
Number of subjects: 289
Study 39674007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hospitalization and intensive care unit stay
Number of subjects: 289
Study 39674007 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence in healthcare
Number of subjects: 289
Study 39674178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Number of subjects: 0
Study 39674369 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbera IGB
Number of subjects: 34
Study 39674369 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatz3 IGB
Number of subjects: 34
Study 39674398 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI/REL (500 mg/250 mg) every 6 h for 7-14 days
Number of subjects: 270
Study 39674398 — intervention group
Group type: COMPARATOR
Intervention: PIP/TAZ (4000 mg/500 mg) every 6 h for 7-14 days
Number of subjects: 270
Study 39674398 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI/REL
Number of subjects: 270
Study 39674398 — intervention group
Group type: COMPARATOR
Intervention: PIP/TAZ
Number of subjects: 270
Study 39674398 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI/REL and PIP/TAZ
Number of subjects: 270
Study 39674524 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine preprocedural PCI (reference group)
Number of subjects: 466
Study 39674524 — intervention group
Group type: COMPARATOR
Intervention: No PCI (index group)
Number of subjects: 466
Study 39674725 — intervention group
Group type: EXPERIMENTAL
Intervention: High animal protein diet (AP)
Number of subjects: 33
Study 39674725 — intervention group
Group type: COMPARATOR
Intervention: High vegetable protein diet (VP)
Number of subjects: 33
Study 39675045 — intervention group
Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Number of subjects: 9
Study 39675045 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative investigations, live donor uterus transplantation, postoperative care, immunosuppression, IVF, follow-up, pregnancy care, delivery, graft removal
Number of subjects: 9
Study 39675110 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Number of subjects: 233
Study 39675110 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors
Number of subjects: 233
Study 39675110 — intervention group
Group type: COMPARATOR
Intervention: Non-progressors
Number of subjects: 233
Study 39675209 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine
Number of subjects: 10416
Study 39675209 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 10416
Study 39675376 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 731
Study 39675376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 731
Study 39675486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus metformin
Number of subjects: 2990
Study 39675486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and metformin dual-therapy
Number of subjects: 2990
Study 39675486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and metformin combination therapy
Number of subjects: 2990
Study 39675486 — intervention group
Group type: COMPARATOR
Intervention: Total population
Number of subjects: 2990
Study 39675563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 47
Study 39675821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive phenotypic evaluation including age, antibodies against glutamic acid decarboxylase, body mass index, glycated haemoglobin (HbA1c), indexes of insulin sensibility (HOMA2-IR) and secretion (HOMA2-beta)
Number of subjects: 1200
Study 39675821 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage with the population database for pragmatic follow-up
Number of subjects: 1200
Study 39675824 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/day)
Number of subjects: 44
Study 39675824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 39675832 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy with Swedescore
Number of subjects: 586
Study 39675832 — intervention group
Group type: COMPARATOR
Intervention: Conventional colposcopy with no Swedescore
Number of subjects: 586
Study 39675949 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program (15 hours over 6 weeks)
Number of subjects: 106
Study 39675949 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 106
Study 39676137 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1701 (30 mg/kg), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m2)
Number of subjects: 62
Study 39676137 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract
Number of subjects: 62
Study 39676465 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for at least 2 years
Number of subjects: 669
Study 39676687 — intervention group
Group type: EXPERIMENTAL
Intervention: ESO-101 (mometasone furoate, 800 μg)
Number of subjects: 43
Study 39676687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 39676687 — intervention group
Group type: EXPERIMENTAL
Intervention: ESO-101
Number of subjects: 43
Study 39676687 — intervention group
Group type: EXPERIMENTAL
Intervention: ESO-101 and Placebo
Number of subjects: 43
Study 39676868 — intervention group
Group type: EXPERIMENTAL
Intervention: IAH0968 (6 mg/kg, 10 mg/kg)
Number of subjects: 18
Study 39676868 — intervention group
Group type: EXPERIMENTAL
Intervention: IAH0968
Number of subjects: 18
Study 39677358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D
Number of subjects: 206
Study 39677358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 39677358 — intervention group
Group type: COMPARATOR
Intervention: Both vitamin D and placebo
Number of subjects: 206
Study 39677360 — intervention group
Group type: EXPERIMENTAL
Intervention: AAP CDA
Number of subjects: 1821
Study 39677360 — intervention group
Group type: EXPERIMENTAL
Intervention: BSAC CDA
Number of subjects: 1821
Study 39677360 — intervention group
Group type: EXPERIMENTAL
Intervention: NICE NG143 CDA
Number of subjects: 1821
Study 39677360 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronson CDA
Number of subjects: 1821
Study 39677360 — intervention group
Group type: COMPARATOR
Intervention: Cost comparison of all CDAs vs treat all approach
Number of subjects: 1821
Study 39677394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation (SpO2) measurement in hospital setting
Number of subjects: 357
Study 39677394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation (SpO2) measurement in follow-up at PHNC
Number of subjects: 357
Study 39678124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase + Methotrexate (MTX)
Number of subjects: 152
Study 39678124 — intervention group
Group type: COMPARATOR
Intervention: Pegloticase + Placebo (PBO)
Number of subjects: 152
Study 39678704 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet
Number of subjects: 1460
Study 39678704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study 39678839 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery sparing the lower mediastinal lymph node dissection (LND)
Number of subjects: 634
Study 39679006 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital coaching (n=200)
Number of subjects: 600
Study 39679006 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=400)
Number of subjects: 600
Study 39679349 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of 50 µg mRNA-1273
Number of subjects: 17000
Study 39679349 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 arm
Number of subjects: 17000
Study 39679349 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-month dosing interval
Number of subjects: 17000
Study 39679566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative bipolar radiofrequency treatment
Number of subjects: 43
Study 39679622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (ImPaC)
Number of subjects: 354
Study 39679749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients (MMN)
Number of subjects: 965
Study 39679749 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Number of subjects: 965
Study 39679749 — intervention group
Group type: COMPARATOR
Intervention: Iron and Folic Acid (IFA)
Number of subjects: 965
Study 39679749 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Environment Quality
Number of subjects: 965
Study 39679979 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community of practice (vCoP) intervention
Number of subjects: 282
Study 39679979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study 39679985 — intervention group
Group type: EXPERIMENTAL
Intervention: Piano practice
Number of subjects: 0
Study 39679985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no piano practice)
Number of subjects: 0
Study 39680321 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous vitamin K1
Number of subjects: 60
Study 39680321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39680390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RIDE trial)
Number of subjects: 759
Study 39680390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RISE trial)
Number of subjects: 759
Study 39680397 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional social transfer
Number of subjects: 298
Study 39680397 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional social transfer
Number of subjects: 298
Study 39680397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 298
Study 39680398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application-based communication platform intervention
Number of subjects: 151
Study 39680398 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 151
Study 39680411 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 400 mg
Number of subjects: 50
Study 39680411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 39680511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 0
Study 39680511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39680515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Steroid Combination in Ocular Trauma (ASCOT)
Number of subjects: 259
Study 39680515 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 259
Study 39680874 — intervention group
Group type: EXPERIMENTAL
Intervention: Share plus intervention
Number of subjects: 80
Study 39680874 — intervention group
Group type: COMPARATOR
Intervention: CGM Follow app plus diabetes self-management education
Number of subjects: 80
Study 39680884 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided OCD program on the mHealth app Intellect (8-day program)
Number of subjects: 225
Study 39680884 — intervention group
Group type: COMPARATOR
Intervention: Active control (cooperation)
Number of subjects: 225
Study 39681072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk odor
Number of subjects: 66
Study 39681072 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 66
Study 39681072 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 39681126 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way SMS communication
Number of subjects: 360
Study 39681126 — intervention group
Group type: COMPARATOR
Intervention: WhatsApp peer-support group
Number of subjects: 360
Study 39681126 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-level feedback counselling
Number of subjects: 360
Study 39681126 — intervention group
Group type: COMPARATOR
Intervention: Monthly counselling
Number of subjects: 360
Study 39681164 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG-rich oil (up to 37 g/day) consumed three times daily for 13 days
Number of subjects: 24
Study 39681397 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative just-in-time expert intubation coaching on a manikin within one hour of infant intubation
Number of subjects: 153
Study 39681397 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (unstructured intraoperative instruction by attending pediatric anesthesiologists)
Number of subjects: 153
Study 39681397 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative just-in-time expert intubation coaching
Number of subjects: 153
Study 39681397 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 153
Study 39681752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral injection technique
Number of subjects: 42
Study 39681752 — intervention group
Group type: COMPARATOR
Intervention: Extraoral injection technique
Number of subjects: 42
Study 39681862 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregiver-targeted web-based psycho-educational intervention (videos and texts about family caregiving)
Number of subjects: 39
Study 39681862 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregiver-targeted web-based psycho-educational intervention
Number of subjects: 39
Study 39681893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellphone ownership
Number of subjects: 2019
Study 39681893 — intervention group
Group type: COMPARATOR
Intervention: Daily cellphone access among non-cellphone owners
Number of subjects: 2019
Study 39681893 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors associated with cellphone ownership
Number of subjects: 2019
Study 39681895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nthabi conversational agent system for family planning education
Number of subjects: 172
Study 39681895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nthabi conversational agent system for folic acid use education
Number of subjects: 172
Study 39682637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention with push notifications once a day
Number of subjects: 0
Study 39682637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile app intervention)
Number of subjects: 0
Study 39683419 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 92
Study 39683419 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics with a healthy diet
Number of subjects: 92
Study 39683612 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation for 12 months
Number of subjects: 160
Study 39683612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 39683612 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 160
Study 39683619 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured eating
Number of subjects: 720
Study 39683619 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive or irregular eating patterns
Number of subjects: 720